<p>Caris Life Sciences, Inc. (NASDAQ:CAI - 獲取免費報告) 的股價在週一創下 52 周新低。該股最低交易價為 22.80 美元，最後交易價為 23.56 美元，成交量為 169898 股。該股此前收盤價為 23.16 美元。</p>
<p>獲取 <strong>Caris Life Sciences</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>幾家券商最近對 CAI 進行了評論。華爾街 Zen 在 1 月 17 日的報告中將 Caris Life Sciences 的評級從 “持有” 上調至 “買入”。Evercore ISI 在 1 月 5 日的研究報告中設定了 Caris Life Sciences 的目標價為 38.00 美元。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Caris Life Sciences 的 “賣出（d）” 評級。最後，Canaccord Genuity Group 在 12 月 22 日的報告中將 Caris Life Sciences 的目標價從 28.00 美元上調至 30.00 美元，並給予該股 “持有” 評級。一位研究分析師對該股給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat 的數據，該股目前的共識評級為 “減持”，共識目標價為 34.00 美元。</p>
<p><strong>查看我們關於 CAI 的最新報告</strong></p>
<h2>Caris Life Sciences 股票表現</h2>
<p>該公司的債務與股本比率為 0.79，流動比率為 9.93，速動比率為 9.36。該股市值為 65.9 億美元，市盈率為-50.80。</p>
<h2>Caris Life Sciences 的內部交易</h2>
<p>在其他新聞中，內部人士 Luke Thomas Power 在 12 月 11 日的交易中出售了 62,250 股該公司的股票。股票以平均價格 26.58 美元出售，總價值為 1,654,605.00 美元。交易後，內部人士持有 99,571 股公司的股票，價值約為 2,646,597.18 美元。此次交易代表其持股減少了 38.47%。該出售在向證券交易委員會提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司 7.80% 的股份。</p>
<h2>Caris Life Sciences 的機構交易</h2>
<p>一些機構投資者和對沖基金最近調整了對 CAI 的持股。Diversified Trust Co.在第四季度以 540,000 美元的估值新建了對 Caris Life Sciences 的持倉。Olistico Wealth LLC 在第四季度以約 31,000 美元的價值購買了 Caris Life Sciences 的新股份。Zevenbergen Capital Investments LLC 在第四季度以約 14,655,000 美元的價值新建了對 Caris Life Sciences 的股份。Hamilton Lane Advisors LLC 在第四季度以約 1,584,000 美元的估值新建了對 Caris Life Sciences 的持倉。最後，Sumitomo Mitsui Trust Group Inc.在第四季度將其在 Caris Life Sciences 的股份增加了 26.5%。Sumitomo Mitsui Trust Group Inc.現在擁有 75,330 股公司的股票，價值 2,032,000 美元，此前在上個季度又購買了 15,778 股。</p>
<h2>Caris Life Sciences 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Caris Life Sciences NASDAQ: CAI 是一家分子科學公司，專注於推進腫瘤學中的精準醫學。該公司開發並提供全面的分子分析服務，旨在識別 DNA、RNA 和蛋白質模式中的可操作生物標誌物。其臨牀服務旨在通過根據腫瘤生物學將患者與靶向療法、免疫療法和相關臨牀試驗匹配，來支持腫瘤科醫生的治療決策。</p>
<p>Caris 提供基於實驗室的診斷測試及相關解釋報告，結合高通量測序和其他分子技術與生物信息學分析。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Caris Life Sciences</li>
<li>股票代碼揭曉：對 “下一個埃隆·馬斯克” 公司的 IPO 前訪問</li>
<li>華爾街警報：買入 AES</li>
<li>黃金警報</li>
<li>警報：在明天市場開盤前拋售這五隻股票！</li>
<li>一項價值數萬億的美國 “出生權” 聲明 - 靜悄悄地激活</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Caris Life Sciences 嗎？</h2>
<p>在考慮 Caris Life Sciences 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Caris Life Sciences 並不在名單上。</p>
<p>雖然 Caris Life Sciences 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Caris Life Sciences (NASDAQ:CAI) 的股票在 $22.80 達到新的 52 周低點，收盤價為 $23.56，交易量為 169,898 股。分析師們的意見不一，Wall Street Zen 將該股票評級上調至 “買入”，而 Weiss Ratings 維持 “賣出” 評級。該股票的共識評級為 “減持”，目標價為 $34.00。內部人士 Luke Thomas Power 出售了 62,250 股，減少了 38.47% 的持股比例。該公司專注於腫瘤學領域的精準醫療，提供分子分析服務</p>

<p>Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report)'s share price hit a new 52-week low on Monday . The stock traded as low as $22.80 and last traded at $23.56, with a volume of 169898 shares. The stock had previously closed at $23.16.</p>
<div class="lb-trans"><p>Caris Life Sciences, Inc. (NASDAQ:CAI - 獲取免費報告) 的股價在週一創下 52 周新低。該股最低交易價為 22.80 美元，最後交易價為 23.56 美元，成交量為 169898 股。該股此前收盤價為 23.16 美元。</p>
</div><p>Get <strong>Caris Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Caris Life Sciences</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several brokerages have recently commented on CAI. Wall Street Zen raised Caris Life Sciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, January 17th. Evercore ISI set a $38.00 price objective on Caris Life Sciences in a research note on Monday, January 5th. Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Finally, Canaccord Genuity Group increased their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a &#34;hold&#34; rating in a report on Monday, December 22nd. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of &#34;Reduce&#34; and a consensus target price of $34.00.</p>
<div class="lb-trans"><p>幾家券商最近對 CAI 進行了評論。華爾街 Zen 在 1 月 17 日的報告中將 Caris Life Sciences 的評級從 “持有” 上調至 “買入”。Evercore ISI 在 1 月 5 日的研究報告中設定了 Caris Life Sciences 的目標價為 38.00 美元。Weiss Ratings 在 12 月 29 日的研究報告中重申了對 Caris Life Sciences 的 “賣出（d）” 評級。最後，Canaccord Genuity Group 在 12 月 22 日的報告中將 Caris Life Sciences 的目標價從 28.00 美元上調至 30.00 美元，並給予該股 “持有” 評級。一位研究分析師對該股給予了 “持有” 評級，另一位則給予了 “賣出” 評級。根據 MarketBeat 的數據，該股目前的共識評級為 “減持”，共識目標價為 34.00 美元。</p>
</div><p><strong>View Our Latest Report on CAI</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CAI 的最新報告</strong></p>
</div><h2>Caris Life Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Caris Life Sciences 股票表現</h2>
</div><p>The company has a debt-to-equity ratio of 0.79, a current ratio of 9.93 and a quick ratio of 9.36. The stock has a market capitalization of $6.59 billion and a price-to-earnings ratio of -50.80.</p>
<div class="lb-trans"><p>該公司的債務與股本比率為 0.79，流動比率為 9.93，速動比率為 9.36。該股市值為 65.9 億美元，市盈率為-50.80。</p>
</div><h2>Insider Transactions at Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的內部交易</h2>
</div><p>In other news, insider Luke Thomas Power sold 62,250 shares of the firm's stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total value of $1,654,605.00. Following the transaction, the insider owned 99,571 shares of the company's stock, valued at approximately $2,646,597.18. This trade represents a 38.47% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own 7.80% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Luke Thomas Power 在 12 月 11 日的交易中出售了 62,250 股該公司的股票。股票以平均價格 26.58 美元出售，總價值為 1,654,605.00 美元。交易後，內部人士持有 99,571 股公司的股票，價值約為 2,646,597.18 美元。此次交易代表其持股減少了 38.47%。該出售在向證券交易委員會提交的文件中披露，文件可通過此超鏈接獲取。內部人士持有公司 7.80% 的股份。</p>
</div><h2>Institutional Trading of Caris Life Sciences</h2>
<div class="lb-trans"><h2>Caris Life Sciences 的機構交易</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of CAI. Diversified Trust Co. acquired a new position in shares of Caris Life Sciences in the 4th quarter valued at $540,000. Olistico Wealth LLC bought a new stake in shares of Caris Life Sciences in the fourth quarter worth about $31,000. Zevenbergen Capital Investments LLC acquired a new stake in shares of Caris Life Sciences during the fourth quarter worth about $14,655,000. Hamilton Lane Advisors LLC acquired a new position in shares of Caris Life Sciences in the 4th quarter valued at approximately $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Caris Life Sciences by 26.5% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company's stock worth $2,032,000 after purchasing an additional 15,778 shares in the last quarter.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近調整了對 CAI 的持股。Diversified Trust Co.在第四季度以 540,000 美元的估值新建了對 Caris Life Sciences 的持倉。Olistico Wealth LLC 在第四季度以約 31,000 美元的價值購買了 Caris Life Sciences 的新股份。Zevenbergen Capital Investments LLC 在第四季度以約 14,655,000 美元的價值新建了對 Caris Life Sciences 的股份。Hamilton Lane Advisors LLC 在第四季度以約 1,584,000 美元的估值新建了對 Caris Life Sciences 的持倉。最後，Sumitomo Mitsui Trust Group Inc.在第四季度將其在 Caris Life Sciences 的股份增加了 26.5%。Sumitomo Mitsui Trust Group Inc.現在擁有 75,330 股公司的股票，價值 2,032,000 美元，此前在上個季度又購買了 15,778 股。</p>
</div><h2>Caris Life Sciences Company Profile</h2>
<div class="lb-trans"><h2>Caris Life Sciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.</p>
<div class="lb-trans"><p>Caris Life Sciences NASDAQ: CAI 是一家分子科學公司，專注於推進腫瘤學中的精準醫學。該公司開發並提供全面的分子分析服務，旨在識別 DNA、RNA 和蛋白質模式中的可操作生物標誌物。其臨牀服務旨在通過根據腫瘤生物學將患者與靶向療法、免疫療法和相關臨牀試驗匹配，來支持腫瘤科醫生的治療決策。</p>
</div><p>Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.</p>
<div class="lb-trans"><p>Caris 提供基於實驗室的診斷測試及相關解釋報告，結合高通量測序和其他分子技術與生物信息學分析。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Caris Life Sciences</li>
<li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li>
<li>Wall Street Alert: Buy AES</li>
<li>GOLD ALERT</li>
<li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Caris Life Sciences</li>
<li>股票代碼揭曉：對 “下一個埃隆·馬斯克” 公司的 IPO 前訪問</li>
<li>華爾街警報：買入 AES</li>
<li>黃金警報</li>
<li>警報：在明天市場開盤前拋售這五隻股票！</li>
<li>一項價值數萬億的美國 “出生權” 聲明 - 靜悄悄地激活</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Caris Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Caris Life Sciences 嗎？</h2>
</div><p>Before you consider Caris Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Caris Life Sciences 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Caris Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Caris Life Sciences 並不在名單上。</p>
</div><p>While Caris Life Sciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Caris Life Sciences 目前在分析師中獲得了減持評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Caris Life Sciences (NASDAQ:CAI) 創下新的一年低點 - 現在是賣出的時候嗎？